The KeyNote 189 study was the first phase III study to demonstrate a greater benefit for the combination of platinum-based CT and pembrolizumab versus CT and placebo in a population of patients with NSCLC EGFR/wild-type ALK and non-squamous histology, including a pre-planned analysis based on PD-L1 expression (negative or positive). Here, EGFR is linked to non-small cell lung carcinoma.